Lymphoma is one of the most common cancers in dogs. Although remission can often be achieved with conventional chemotherapy, relapse is common and novel approaches are needed. Survivin, a protein that promotes cell growth and inhibits cell death, is found in many human and canine cancers. A high level of survivin is associated with a worse outcome for dogs with lymphoma. Researchers will evaluate the safety and effectiveness of a therapeutic agent designed to inhibit the production of survivin in dogs with lymphoma. They will also evaluate how this agent affects lymphoma cell growth and death. If researchers can establish a biologically effective dose, it would provide a working dosage for future clinical trials that would combine this therapy with standard chemotherapy.
Study ID
D14CA-061
Study Status
Complete
Start Date
09/01/2013
Grant amount awarded
$105,131
Grant recipient
Colorado State University
Study country
United States
Investigator
Douglas H. Thamm, VMD
Study category
Cancer